The company PR's provide a solid timeline regarding the company's progress this year. A good place to start.
Some information.
- little to no debt, inventory levels have been increasing, very solid asset to debt ratio - Two new product lines were launched this year (Steri-Tap and bariatric). The Steri-Tap is approved for marketing and sales in both the US and Europe due to it being manufactured overseas. - Solos Mammoview used by National Institute of Health in a research capacity for the last 6-8 years. - Targeting early in the 1Q for the CE Mark approval for the Mammoview and bariatric product lines. - Current Deposit Chill affecting Apex Clearing and TDAmeritradeand has not spread to other brokerages. Management has already came out and addressed the issue. - Based on the Oct numbers just released, it looks like the company is beginning to generate revenue from the Steri-Tap product line (Initial marketing efforts began in July). 4Q revenue projections look really good. - President's Letters on the company website indicate management is actively pursuing either partnership (organic growth) or merger